Cited 0 times in
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2023-07-12T02:25:28Z | - |
dc.date.available | 2023-07-12T02:25:28Z | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 1479-6694 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195305 | - |
dc.description.abstract | Aim: Report the final analysis from ASTRIS, the largest real-world study of second-/later-line osimertinib in advanced/metastatic EGFR T790M non-small-cell lung cancer (NSCLC). Methods: Patients with advanced/metastatic EGFR T790M NSCLC and prior EGFR-TKI treatment, received once-daily osimertinib 80 mg. Primary end point: overall survival (OS); secondary end points: progression-free survival (PFS), time-to-treatment discontinuation (TTD) and response rate. Safety was also recorded. Results: In 3014 patients, median OS: 22.8 months (21.6-23.8), median PFS: 11.1 months (11.0-12.0), median TTD: 13.5 months (12.6-13.9), and response rate: 57.3% (55.5-59.2). All end points reported with 95% CIs. Numerically longer median OS was observed in patients with baseline WHO performance status <2 versus 2 (24.0 vs 11.1 months) and those without versus with brain/leptomeningeal metastases (25.4 vs 18.0 months). No new safety signals were identified. Conclusion: Second-/later-line osimertinib demonstrated real-world clinical benefit and safety in advanced/metastatic EGFR T790M NSCLC. Clinical Trial Registration: NCT02474355 (ClinicalTrials.gov). | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Future Medicine Ltd. | - |
dc.relation.isPartOf | FUTURE ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Aniline Compounds / adverse effects | - |
dc.subject.MESH | Brain Neoplasms* / drug therapy | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* / drug therapy | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* / genetics | - |
dc.subject.MESH | ErbB Receptors / genetics | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms* / drug therapy | - |
dc.subject.MESH | Lung Neoplasms* / genetics | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Protein Kinase Inhibitors / adverse effects | - |
dc.title | A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Parneet Cheema | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Helano Freitas | - |
dc.contributor.googleauthor | Mariano Provencio | - |
dc.contributor.googleauthor | Yuh Min Chen | - |
dc.contributor.googleauthor | Sang-We Kim | - |
dc.contributor.googleauthor | Yi-Long Wu | - |
dc.contributor.googleauthor | Antonio Passaro | - |
dc.contributor.googleauthor | Claudio Martin | - |
dc.contributor.googleauthor | Marcello Tiseo | - |
dc.contributor.googleauthor | Gee-Chen Chang | - |
dc.contributor.googleauthor | Keunchil Park | - |
dc.contributor.googleauthor | Benjamin Solomon | - |
dc.contributor.googleauthor | Otto Burghuber | - |
dc.contributor.googleauthor | Janessa Laskin | - |
dc.contributor.googleauthor | Ziping Wang | - |
dc.contributor.googleauthor | Sung Yong Lee | - |
dc.contributor.googleauthor | Yanping Hu | - |
dc.contributor.googleauthor | Johan Vansteenkiste | - |
dc.contributor.googleauthor | He-Long Zhang | - |
dc.contributor.googleauthor | Emer Hanrahan | - |
dc.contributor.googleauthor | Thomas Geldart | - |
dc.contributor.googleauthor | Rosemary Taylor | - |
dc.contributor.googleauthor | Leslie Servidio | - |
dc.contributor.googleauthor | Jingyi Li | - |
dc.contributor.googleauthor | Filippo de Marinis | - |
dc.identifier.doi | 10.2217/fon-2022-0919 | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J00914 | - |
dc.identifier.eissn | 1744-8301 | - |
dc.identifier.pmid | 36656302 | - |
dc.identifier.url | https://www.futuremedicine.com/doi/10.2217/fon-2022-0919 | - |
dc.subject.keyword | EGFR | - |
dc.subject.keyword | T790M | - |
dc.subject.keyword | non-small-cell lung cancer | - |
dc.subject.keyword | osimertinib | - |
dc.subject.keyword | real world | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | 조병철 | - |
dc.citation.volume | 19 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 61 | - |
dc.citation.endPage | 75 | - |
dc.identifier.bibliographicCitation | FUTURE ONCOLOGY, Vol.19(1) : 61-75, 2023-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.